title: Successful Omalizumab treatment in HIV positive patient with chronic spontaneous urticaria: a case report.
abstract: We described a case of a 56 year old homosexual HIV positive man who presented a history of CSU since one year (2012). All the allergologic, immunologic and microbiologic tests to evaluate the pathogenesis of wheals resulted negative. Therefore in June 2015 we decided to start therapy with Omalizumab while the patient kept on effective antiretroviral therapy with 310 cells/mm3 TCD4 counts and undetectable HIV viremia. After two monthly subcutaneuous injection of 150 mg of Omalizumab the patient had no more urticarial symptoms. UAS7 (Urticaria Activity Score over 7 days) and Cu-Q2oL (chronic urticarial quality of life questionnaire) dropped respectively to 14 from 42 and to 0 from 40 with increase of TCD4 counts while viral load remained undetectable. In November 2015, i.e. 4 months after the end of Omalizumab therapy, the patient was still asymptomatic with persistent effective immune-virological response to antiretroviral therapy. This case report confirms the excellent tolerability and efficacy of anti-IgE therapy in the treatment of spontaneous chronic urticarial even in an immunodepressed patient for HIV infection. Omalizumab therapy shows a remarkable clinical success and had no effect on peripheral TCD4 counts and HIV viral load.
authors.affiliation: Allergy and Clinical Immunology and 1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Iemoli
authors.affiliation: Allergy and Clinical Immunology and 1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Niero
authors.affiliation: Allergy and Clinical Immunology and 1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy. E-mail: linda.borgonovo@gmail.com.
authors.forename: L
authors.initials: L
authors.lastname: Borgonovo
authors.affiliation: Allergy and Clinical Immunology and 1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy.
authors.forename: M V
authors.initials: MV
authors.lastname: Cossu
authors.affiliation: Allergy and Clinical Immunology and 1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Piconi
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002908:Chronic Disease; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab / Q000627:therapeutic use*; D016896:Treatment Outcome; D014581:Urticaria / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D019562:Viral Load
chemical_list: D018926:Anti-Allergic Agents; D019380:Anti-HIV Agents; D000069444:Omalizumab
keywords: HIV-positive; Omalizumab; chronic spontaneous urticaria